Dual therapy (ritonavir boosted atazanavir + raltegravir) versus standard triple therapy (ritonavir boosted atazanavir + tenofovir/emtricitabine) in patients failing first line therapy: 48 week results from a randomized pilot study. (August 2018) - Sued, O.; Figueroa, M.I.; Cesar, C.; Patterson, P.; Yamamoto, C.; fink, V.; luna, N.; Gun, A.; Cahn, P.